Bioscript

Bioscript is a leading commercialisation services agency specialising in medical communications, medical affairs strategy, market access and regulatory writing. Founded in 2005, it has been setting industry standards for almost 20 years and is today recognised as one of the fastest growing medical communications agencies in the UK.

Sovereign invested in Bioscript in 2021, partnering with the founder and management team who were keen to develop the business further through a strategy of Buy & Build.

Planned succession for the founder with the appointment of a new CEO, and investment into the senior leadership across business development, human resources, finance and operations.

Acquisition of four UK-based agencies to add capabilities across medical affairs strategy and market access whilst building scale within medical communications.

Team has grown from around 90 in 2021 to 250 as of 2023.

Bioscript Group is one of the largest independent global agencies, with a strong international reputation for high-quality medical communications, regulatory writing and market access consultancy.

The business assists clients in their communications with regulatory authorities as well as educating the medical sector on pharmaceutical products that are in mid- to late-stage clinical trials and subsequently supporting these products, post-market launch, to maintain and grow sales throughout the lifecycle of the drug.

Acquisitions to date:

• Fortis Pharma Consulting, a medical affairs services provider that works with clients in refining and articulating a product’s value at launch
• Valid Insight, an award-winning market access consultancy that helps clients to deliver pricing, reimbursement, market access and payer value communication strategies through the full product development cycle
• Meridian HealthComms, a successful operator with particular strengths in scientific and clinical communications, strategic planning and brand management
• Enzyme Communications, a science communications and marketing agency, specialising in oncology and rare diseases

The acquisitions have strengthened Bioscript's end-to-end service offering by extending the breadth and depth of its services across the pharmaceutical product lifecycle, and have brought additional capabilities in medical affairs, global market access strategy and payer value communications.

The combined group brings together experts in healthcare communications globally with a focus on scientific and writing excellence, expert engagement, events management, strategic planning and patient access consulting for pharmaceutical and biotech companies.

Today the Group also provides clients with extended support across integrated medical communication programmes, from very early clinical development through to market access communications.